Potvin method is acceptable or not for FDA [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2022-03-21 12:37 (67 d 04:43 ago) – Posting: # 22855
Views: 418


» Potvin method is acceptable or not for FDA,
» If yes how,
» if no why

Regulators tend not to give informative reasons.
But the answer to your question is yes, Potvin is acceptable. Do a controlled corr. with FDA to make sure you get everything right.
In particular, you may get a high CV by chance (risk increases if initial sample size is low, like n1=12) and this high CV may cause your sample size for stage 2 to become big, like 400 subjects. If you decide to cap sample size (like we will only go ahead with stage if n2 <80 or whatever), then the method has new properties in terms of power and type I error and you are expected to be able to present data for that if the agency asks. In general, your power drops a lot if you use such caps. You need to be absolutely aware of it, otherwise you'll be initiating a study that may have a very low chance of success even if power for stage 2 is set at 80% or higher.

Pass or fail!

Complete thread:

UA Flag
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Friday 18:21 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz